CLTX Mechanism

CLTX Mechanism2020-09-21T06:29:36+00:00
  • We have developed and optimized a CAR T cell therapy utilizing the chlorotoxin peptide (CLTX) as the CAR tumor recognition domain and established potent antitumor activity against glioblastoma (GBM)
  • CLTX-CAR T cells specifically and broadly target GBM through recognition of a receptor complex composed of membrane-bound matrix metalloprotease 2 (MMP2) and involving the chloride channel CLC3
  • CLTX-CAR T cells do not exhibit off-tumor recognition of normal human or murine cells/tissues in preclinical models, consistent with the documented safety of administering other CLTX-containing therapeutic agents in humans